Posts

Trump rape case: Lawyer blasts the former president's offer to finally submit DNA as a 'bad faith' delay tactic

  Trump rape case: Lawyer blasts the former president's offer to finally submit DNA as a 'bad faith' delay tactic Trump is now willing to submit a DNA sample for his civil rape case in NY, new court papers say. The deadline for new evidence has passed, so it's unclear if the sample will come into play at trial. Carroll's attorney called the offer "yet another bad faith and legally frivolous delay tactic."  Loading Something is loading. Thanks for signing up!Access your favorite topics in a personalized feed while you're on the go. download the appFormer President Donald Trump has agreed to undergo DNA testing as part of his defense in an upcoming civil rape trial in New York federal court, but lawyers for his accuser say the offer is coming too late and is just another delay tactic.  Trump's sudden willingness to submit a DNA sample after discovery in the case has ended — and after three years of denying the request — was confirmed in court papers...
Post a Comment
Read more

Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings

  Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel). The analysis showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), with a consistent safety profile observed since the two-year analysis. In the Phase 2 treated patient cohort (n=55), the median follow-up was 38.8 months. The OS rate at 36.0 months was 47.1%, with a median OS of 26.0 months among all treated Phase 2 patients (n=55) and 38.9 months in patients with complete remission (CR) or complete remission with incomplete hematologic recovery (CRi; n=39).
Post a Comment
Read more